Beta Bionics Partners with Senseonics to Integrate iLet and mint with Eversense 365
BBNX has more than doubled off its 52-week low of $8.8.
Summary
Beta Bionics announced a partnership with Senseonics to integrate its iLet Bionic Pancreas and mint AID systems with Senseonics' Eversense 365 CGM. Commercial launch of the integrated iLet and Eversense 365 system is expected in Q4 2026, positioning iLet to support the most CGM manufacturer options of any AID system. This expands Beta Bionics' addressable market by offering patients a year-long implantable CGM option, a differentiator versus competitors. The deal follows the recent FDA clearance of mint and a $172.5M capital raise, giving the company resources to execute the integration.
At the time of this announcement, BBNX was trading at $22.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $8.80 to $32.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.